These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 35204677)

  • 21. Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction.
    van Woerden G; van Veldhuisen DJ; Manintveld OC; van Empel VPM; Willems TP; de Boer RA; Rienstra M; Westenbrink BD; Gorter TM
    Circ Heart Fail; 2022 Mar; 15(3):e009238. PubMed ID: 34935412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschöpe C; Hoes AW; Seferović JP; Logue J; McDonagh T; Riley JP; Milinković I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV
    Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction.
    Gorter TM; van Woerden G; Rienstra M; Dickinson MG; Hummel YM; Voors AA; Hoendermis ES; van Veldhuisen DJ
    JACC Heart Fail; 2020 Aug; 8(8):667-676. PubMed ID: 32653444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.
    Lin SN; Phang KK; Toh SH; Chee KH; Zaman Huri H
    Front Endocrinol (Lausanne); 2020; 11():448. PubMed ID: 32754118
    [No Abstract]   [Full Text] [Related]  

  • 25. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.
    Iwakura K
    J Echocardiogr; 2019 Dec; 17(4):177-186. PubMed ID: 31617144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction.
    Nashawi M; Sheikh O; Battisha A; Mir M; Chilton R
    Heart Fail Rev; 2022 Jan; 27(1):219-234. PubMed ID: 32583230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Intern Med; 2021; 60(15):2367-2374. PubMed ID: 34334588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    Packer M; Kitzman DW
    JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients.
    Wu CK; Tsai HY; Su MM; Wu YF; Hwang JJ; Lin JL; Lin LY; Chen JJ
    J Clin Lipidol; 2017; 11(6):1421-1431. PubMed ID: 29050981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease.
    Packer M; Lam CSP; Lund LH; Maurer MS; Borlaug BA
    Eur J Heart Fail; 2020 Sep; 22(9):1551-1567. PubMed ID: 32441863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic analysis of epicardial adipose tissue from heart disease patients with concomitant heart failure with preserved ejection fraction.
    He S; Zhu H; Zhang J; Wu X; Zhao L; Yang X
    Int J Cardiol; 2022 Sep; 362():118-125. PubMed ID: 35662556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue and Myocardial Microcirculation by MRI in Postmenopausal Women.
    Huang S; Li Y; Jiang L; Ren Y; Wang J; Shi K; Yan WF; Qian WL; Yang ZG
    J Magn Reson Imaging; 2022 Nov; 56(5):1404-1413. PubMed ID: 35179821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2019 Apr; 47(2):67-72. PubMed ID: 30712418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].
    Kobalava ZD; Yeshniyazov NV; Medovchshikov VV; Khasanova ER
    Kardiologiia; 2019 Apr; 59(4):76-87. PubMed ID: 31002044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium.
    Packer M
    J Am Coll Cardiol; 2018 May; 71(20):2360-2372. PubMed ID: 29773163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease.
    Packer M
    Am J Med; 2020 Feb; 133(2):170-177. PubMed ID: 31622581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.